Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64
Guggenheim analyst Paul Jeng assumes Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Target of $64.
Stocks · News reference
Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.82) per share. This is a 583.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $6.533 million in sales
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nanobiotix Says JNJ-1900 (NBTXR3) Shows 61% One-Year Local Progression-Free Survival And 70% One-Year Overall Survival In Phase 1 NSCLC Trial
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.